High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer

Pancreatic adenocarcinomas with mature blood vessels have better overall survival

(2019) Eriko Katsuta et al.   Scientific Reports

Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival

(2019) Maiko Okano et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Triple-Negative Breast Cancer with High Levels of Annexin A1 Expression Is Associated with Mast Cell Infiltration, Inflammation, and Angiogenesis

(2019) Maiko Okano et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptor‑positive breast cancer

(2019) Eriko Katsuta et al.   ONCOLOGY REPORTS

High expression of SLCO2B1 is associated with prostate cancer recurrence after radical prostatectomy

(2018) Tomoaki Terakawa et al.   Oncotarget

Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis

(2018) Yuki Hirose et al.   Scientific Reports

Expression of MicroRNA-9 is Associated With Overall Survival in Breast Cancer Patients

(2018) Judith C. Sporn et al.   JOURNAL OF SURGICAL RESEARCH

Low DMT1 Expression Associates With Increased Oxidative Phosphorylation and Early Recurrence in Hepatocellular Carcinoma

(2018) Toshifumi Hoki et al.   JOURNAL OF SURGICAL RESEARCH

Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer

(2017) Eriko Katsuta et al.   JOURNAL OF SURGICAL RESEARCH

MYC overexpression with its prognostic and clinicopathological significance in breast cancer

(2017) Jingkun Qu et al.   Oncotarget

High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer

(2017) Nidhi Gupta et al.   Oncotarget

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression

(2016) Dai Horiuchi et al.   NATURE MEDICINE

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

(2016) Bernard Pereira et al.   Nature Communications

MYC, Metabolism, and Cancer

(2015) Z. E. Stine et al.   Cancer Discovery

The Molecular Signatures Database Hallmark Gene Set Collection

(2015) Arthur Liberzon et al.   Cell Systems

Pan-cancer patterns of somatic copy number alteration

(2013) Travis I Zack et al.   NATURE GENETICS

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency

(2013) Jie Ren et al.   TUMOR BIOLOGY

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

(2012) Dai Horiuchi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Wnt/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome

(2010) Andrey I. Khramtsov et al.   AMERICAN JOURNAL OF PATHOLOGY

Cytoplasmic Localization of  -Catenin is a Marker of Poor Outcome in Breast Cancer Patients

(2010) E. Lopez-Knowles et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

The Cell Cycle and Myc Intersect with Mechanisms that Regulate Pluripotency and Reprogramming

(2009) Amar M. Singh et al.   Cell Stem Cell

Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup

(2009) M. Chehani Alles et al.   PLoS One

A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response

(2009) Sanjay Chandriani et al.   PLoS One

MYC in breast tumor progression

(2008) Yinghua Chen et al.   Expert Review of Anticancer Therapy

Modelling Myc inhibition as a cancer therapy

(2008) Laura Soucek et al.   NATURE